Overview

Caduet in an Untreated Subject Population

Status:
Completed

Trial end date:
2007-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if Caduet will lower blood pressure to <140/90 mmHg and lower LDL Cholesterol to <100 mg/dL in subjects with hypertension and dyslipidemia who are not currently being treated for these medical conditions.

Phase:

Phase 4

Details

Lead Sponsor:

Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatments:

Amlodipine, atorvastatin drug combination